Kimia Therapeutics, Inc. (Kimia), a biotechnology company generating a chemical atlas for treating human disease, today announced that it has closed a $55 million Series A financing. The Column Group and Dimension led the Series A round and was joined by Horizons Ventures and individual investors. The funding will enable Kimia to expand its ATLAS platform and pursue a broad range of therapeutic targets in oncology, immunology and inflammation while continuing to partner with Carmot Therapeutics Inc